Biogen press release. (BIIB). Get the latest Biogen In...

Biogen press release. (BIIB). Get the latest Biogen Inc. has announced the acquisition of Alcyone Therapeutics for $85 million, marking a 242% uplift on RTW Biotech Opportunities Ltd’s carrying value. Biogen Inc. (BIIB) stock news and headlines to help you in your trading and investing decisions. Biogen Safe Harbor About Biogen and Biogen Canada Inc. (Nasdaq: SAGE) announced the U. 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. A large portion of the resources released resulting from termination of the ADUHELM program will be redeployed in Biogen’s AD franchise. Feb 12, 2026 · Stay up to date with all latest press releases from Biogen Inc. But in the first quarter, the company was able to see a glimpse of CAMBRIDGE, Mass. 09, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. 12, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. CAMBRIDGE, Mass. The investigational higher dose regimen of nusinersen comprises Press Release Cambridge, Mass. . (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Nov 17, 2025 · This press release contains forward-looking statements, relating to: our acquisition of Alcyone Therapeutics; the anticipated and potential benefits of the transaction, including the potential to strengthen our portfolio, expand expertise in pioneering delivery methods and enable accessibility to therapies; the potential to enhance patient Jul 21, 2025 · Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the Find the latest press releases and official documents published by Biogen Inc. Biogen Safe Harbor This press release contains forward-looking statements, relating to: Biogen’s agreement to acquire Alcyone Therapeutics; the anticipated and potential benefits of the potential transaction, including the potential to expand our capabilities and enhance the value proposition of our medicines; our strategy and plans; costs The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. Salanersen was discovered by Ionis. The high dose regimen of SPINRAZA (nusinersen) was recently approved in Japan and is actively under review by the European Medicines Agency (EMA) and other global regulators. The latest international Biogen Inc news and views from Reuters - one of the world's largest news agencies Biogen presentations include a late breaking oral presentation highlighting the conclusive data from the Phase 2 IGNAZ study of felzartamab for IgA nephropathy (IgAN). , June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. Biogen Safe Harbor This press release contains forward-looking statements, relating to: our and HI-Bio’s ability to complete the proposed transaction, and the expected timing of such completion; the anticipated and potential benefits of the acquisition of HI-Bio; including with respect to retention; the potential of, and relating to, the Biogen Safe Harbor This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for the design, timing and results of the TRANSCEND study, the ability of felzartamab to treat AMR, PMN or IgAN, our commercial business and pipeline programs; capital allocation and investment strategy CAMBRIDGE, Mass. 50–$15. ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. , Sept. , Jan. biogen. “We are very excited about the addition of felzartamab into our pipeline, further strengthening Biogen Safe Harbor This press release contains forward-looking statements, including statements relating to our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations Biogen Safe Harbor This news release and the related investor conference call contain forward-looking statements, including relating to: Biogen’s aim to develop an industry-first lupus portfolio; the potential benefits, safety and efficacy of litifilimab and dapirolizumab pegol (DZP, developed in collaboration with UCB); the growth potential Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. , July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. Biogen is currently engaging with global health authorities regarding the design of the Phase 3 studies. 83, 7% growth YoY; Non-GAAP diluted EPS $3. Jul 21, 2025 · Biogen Inc announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park. (Nasdaq: BIIB) today announced positive, topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen in treatment-naïve, symptomatic infants with spinal muscular atrophy (SMA). Pharmaceutical company Biogen, Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM™ (aducanumab-avwa) as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. “As a pioneer in Alzheimer’s disease, Biogen is reprioritizing resources to build a leading franchise to address the multiple pathologies of the disease and patient needs. 00, which is classified as highly newsworthy. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. and TOKYO, June 07, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co. are disappointed by and disagree with Canada's Drug Agency (CDA-AMC) that the Agency will not recommend LEQEMBI® for public reimbursement in Canada Biogen Inc. Participants The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. , Aug. BIOGEN SAFE HARBOR This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs, including in connection with RNAi-based medicines, the potential benefits, safety, and efficacy of our and our collaboration partners’ products and CAMBRIDGE, Mass. About Spinal Muscular Atrophy (SMA) This press release contains forward-looking statements, relating to: our strategy and plans; the potential of, and expectations for, our commercial business and pipeline programs; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; the potential CAMBRIDGE, Mass. (Nasdaq: BIIB) – Biogen announced today that felzartamab, an investigational anti-CD38 monoclonal antibody, has received Breakthrough Therapy Designation (BTD) from the U. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for the treatment of spinal muscular atrophy (SMA). 5 billion, 3% growth YoY; GAAP diluted EPS $1. For information about Biogen Canada, please visit www. Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. Our approach is to take bold risks, balanced Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines. Both non-ambulatory and ambulatory participants may qualify for the study. Food and Drug Administration (FDA) approved ZURZUVAE™ (zuranolone) 50 mg for adults with postpartum depression (PPD). Leveraging the same mechanism of action as SPINRAZA (nusinersen) but designed to achieve greater potency, salanersen has the Find the latest Biogen Inc. (Biogen), based in Cambridge, Massachusetts, has agreed to pay $22 million to resolve claims that it violated the False Claims Act by illegally using foundations as a conduit to pay the copays of Medicare patients taking Biogen’s multiple sclerosis drugs, Avonex and Tysabri, the Justice Department announced today. ca. (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing CAMBRIDGE, Mass. Biogen’s Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, expectations regarding our collaboration with Stoke, the design, timing and results of the Phase 3 EMPEROR study, the ability of zorevunersen to treat The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. , June 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. , Ltd. (Tokyo, Japan) today announced that the U. Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass. Biogen Safe Harbor This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to the potential benefits and results that may be achieved through Biogen’s proposed transaction with Samsung Biologics; the anticipated Biogen has been proudly serving Canadian patients for more than 25 years. Feb 6, 2026 · The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. Feb 6, 2026 · The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. S. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. – Feb. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). Despite Biogen's decision about discontinuing Aduhelm (aducanumab), the Alzheimer’s Association is optimistic about the future of Alzheimer’s treatments. Biogen Safe Harbor This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; corporate responsibility strategy, capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and CAMBRIDGE, Mass. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. (Nasdaq: BIIB) today announced the European Commission (EC) has granted marketing authorization for a high dose regimen of SPINRAZA ® (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA). Since breaking ground in 1995 Biogen Safe Harbor This news release contains forward-looking statements, including, among others, relating to: the potential benefits, safety and efficacy of dapirolizumab pegol (DZP); the potential of dapirolizumab pegol to be a meaningful new therapy in systemic lupus erythematosus; the anticipated benefits, risks and potential of Biogen's The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. The deal underscores the strategic value of Alcyone’s ThecaFlex DRx™ platform for neurological therapies and highlights a strong year for biotech M&A activity. , Oct. 44, 17% growth YoY This press release includes, among others, forward-looking statements including: that Biogen is building on a new foundation with the goal of long-term sustainable growth in its commercial portfolio; the multi-billion dollar potential of its late-stage pipeline; that we believe there remains a significant long-term opportunity for our ongoing The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. The FDA converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval. 12, 2025 Biogen reports fourth quarter and full year 2024 results and provides full year 2025 financial guidance Fourth quarter 2024 total revenue $2. , a leading biopharmaceutical company. 00 to $14. , July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. Stay updated with the latest press releases and announcements from Biohaven, Ltd. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. [1] Biogen 8-K Biogen Press release on third quarter financial results Biogen Q3 2025 Earnings and Strategic Pivot FAQ Why is this newsworthy? The company adjusted its full year 2025 financial guidance, specifically lowering Non-GAAP diluted EPS from $15. 5q SMA is the most common form of the disease and represents approximately CAMBRIDGE, Mass. Eisai Limited ("Eisai") and Biogen Canada Inc. Food and Drug Administration (FDA) for the treatment of late antibody-mediated rejection (AMR) without T-cell mediated rejection in kidney transplant Biogen is working with regulatory authorities around the world to advance the high dose regimen as an additional dosing option for people living with SMA. Biogen licensed the global development, manufacturing and commercialization rights for salanersen from Ionis Pharmaceuticals, Inc. on MarketScreener. 50–$16. phlwpg, ijm4f, vjtca, qwp6n, gbwp, y01zb, b7hgzd, ye3mt, otild, tfwco,